Targeting the G2/M Checkpoint in Glioblastoma with a Combined Loss of TP53 and CDKN2A

Abstract

This proposal aims to evaluate the effectiveness of G2/M checkpoint inhibitors as single therapeutic agent, or in combination with radiotherapy, a current standard therapy in GBM, as well as aims to identify new biomarkers for CHK1/2 sensitive GBMs. Successful completion of the aims will help us examine the effects of a new therapeutic strategy against GBM in specific molecular context.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Aug 01, 2020
Accession Number
AD1109492

Entities

People

  • Sangita Pal

Organizations

  • Dana–Farber Cancer Institute

Tags

DTIC Thesaurus Topics

  • Biomedical Research
  • Cancer
  • Cell Line
  • Cell Physiological Processes
  • Data Analysis
  • Data Science
  • Department Of Defense
  • Genetics
  • Governments
  • Inhibition
  • Inhibitors
  • Lethality
  • Local Governments
  • Lung Cancer
  • Medical Personnel
  • Neoplasms
  • Oncology
  • Professional Development
  • Standards
  • Students
  • Targeting
  • Therapy
  • Transcription Factors
  • United States

Fields of Study

  • Biology
  • Chemistry

Readers

  • Mathematics or Statistics
  • Oncology